http://rdf.ncbi.nlm.nih.gov/pubchem/patent/TW-201837046-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5f683349ec51134246442157fc2ca82a |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F5-02 |
| filingDate | 2017-04-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d29cb025400938a51369c1bbdc1437c8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ed293df749dfa3e276b0572fec2feaac http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_49dc997dc9794a6295b1a1784fa37747 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fe5a2b40aa300a0483badaaef656cbaa |
| publicationDate | 2018-10-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | TW-201837046-A |
| titleOfInvention | Method for producing Ixazomib citric acid intermediate and ixam citric acid manufactured using the same |
| abstract | The invention relates to a method for preparing an Ixazomib citric acid intermediate, which can reduce the impurity compound of the oxacin citric acid intermediate and improve the purity, and use the ixam citric acid of the invention. The citric acid prepared by the intermediate is also high in purity and can be used as an active ingredient of a pharmaceutical composition as a protease inhibitor for treating diseases. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110357787-A |
| priorityDate | 2017-04-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 56.